RxDoctor Payments DataLook up a doctor →

June Mayer

Adult Health · Bloomfield, NJNPI 1174571335

Payments from drug & device makers

$7,880in general payments, 2019–2025

Across 486 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$803
  • Boehringer Ingelheim$738
  • Lilly USA, LLC$585
  • GSK$579
  • Amgen$418
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,68898%
  • Education$1922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,880 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$172,755
Medicare patients
379
Services billed
2,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$87,712
JardianceEmpagliflozin90$79,133
EliquisApixaban66$45,641
FarxigaDapagliflozin Propanediol52$43,139
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$34,750
MounjaroTirzepatide33$32,004
JanumetSitagliptin Phos/Metformin Hcl22$29,525
XareltoRivaroxaban22$27,207
JanuviaSitagliptin Phosphate19$25,816
TrulicityDulaglutide16$19,265
Breo ElliptaFluticasone/Vilanterol25$13,785
VascepaIcosapent Ethyl19$12,092
TradjentaLinagliptin13$8,671
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,015
Atorvastatin Calcium375$4,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$738$87,803103 claims
Novo NordiskOzempic$803$87,71273 claims
MerckJanumet, Januvia$129$55,34141 claims
Lilly USA, LLCMounjaro, Trulicity$585$51,26949 claims
GSKTrelegy Ellipta, Breo Ellipta$579$48,53578 claims
PfizerEliquis$122$45,64166 claims
AstraZenecaFarxiga$1,083$43,13952 claims
Johnson & JohnsonXarelto$27$27,20722 claims
Kowa Pharmaceuticals America, Inc.Bystolic$192$3,88012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Bloomfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →